NextCure (NASDAQ:NXTC) Releases Earnings Results, Misses Estimates By $0.85 EPS

NextCure (NASDAQ:NXTC) announced its earnings results on Thursday. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.95) by ($0.85), FiscalAI reports.

NextCure Stock Up 4.5%

NASDAQ:NXTC traded up $0.25 during trading hours on Friday, hitting $5.84. 290,316 shares of the company’s stock traded hands, compared to its average volume of 6,419,686. The stock’s fifty day moving average price is $3.35 and its two-hundred day moving average price is $8.41. NextCure has a twelve month low of $1.55 and a twelve month high of $15.74.

Insider Buying and Selling

In other NextCure news, major shareholder Adar1 Capital Management, Llc bought 36,303 shares of the stock in a transaction on Friday, July 31st. The shares were bought at an average price of $4.94 per share, with a total value of $179,336.82. Following the purchase, the insider directly owned 722,419 shares in the company, valued at $3,568,749.86. The trade was a 5.29% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders bought 346,761 shares of company stock worth $1,710,807. Company insiders own 11.90% of the company’s stock.

Institutional Trading of NextCure

A number of hedge funds have recently made changes to their positions in the stock. Ikarian Capital LLC acquired a new position in shares of NextCure in the fourth quarter worth $3,382,000. Squadron Capital Management LLC purchased a new stake in shares of NextCure during the fourth quarter worth $3,363,000. Exome Asset Management LLC purchased a new stake in shares of NextCure during the fourth quarter worth $2,341,000. AWM Investment Company Inc. acquired a new stake in NextCure during the fourth quarter valued at $1,665,000. Finally, Cable Car Capital LP boosted its position in NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after purchasing an additional 88,040 shares during the last quarter. 42.65% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on NXTC shares. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Zacks Research raised shares of NextCure from a “strong sell” rating to a “hold” rating in a research report on Thursday, June 11th. Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Finally, HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of NextCure in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, NextCure has an average rating of “Hold” and a consensus target price of $19.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.